Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Express Scripts
Medtronic
Mallinckrodt
Johnson and Johnson

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 4,765,989

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 4,765,989
Title: Osmotic device for administering certain drugs
Abstract:An osmotic system is disclosed comprising a wall comprising in at least a part of a semipermeable material that surrounds a compartment. The compartment contains an osmotic composition comprising a beneficial drug selected from the group consisting of nifedipine, prazosin and doxazosin, and a second and different osmotic composition. A passageway in the wall connects the first composition with the exterior of the system.
Inventor(s): Wong; Patrick S. L. (Hayward, CA), Barclay; Brian L. (Sunnyvale, CA), Deters; Joseph C. (Mt. View, CA), Theeuwes; Felix (Los Altos, CA)
Assignee: Alza Corporation (Palo Alto, CA)
Application Number:06/902,915
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 4,765,989
Patent Claim Types:
see list of patent claims
Dosage form; Device; Composition; Delivery; Use;

Drugs Protected by US Patent 4,765,989

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 4,765,989

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 394944   Start Trial
Austria 397180   Start Trial
Austria A150789   Start Trial
Austria A88084   Start Trial
Australia 2251183   Start Trial
Australia 566110   Start Trial
Belgium 898819   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Colorcon
Boehringer Ingelheim
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.